Latest Information Update: 27 Nov 2007
At a glance
- Originator Immtech Pharmaceuticals; Nonindustrial source
- Class Antifungals
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 14 Oct 2002 No development reported - Preclinical for Mycoses in USA (unspecified route)
- 16 May 2000 Preclinical development for Mycoses in USA (Unknown route)